Radiation treatment in age-related macular degeneration

Christina J. Flaxel, Paul T. Finger

Research output: Chapter in Book/Report/Conference proceedingChapter


Age-related macular degeneration (AMD) is a leading cause of rapid and severe visual loss and legal blindness in developed countries (1,2). Ten million Americans are visually disabled due to AMD and 10% of patients aged 66 to 74 show signs of AMD (3,4). Estimated prevalence is from 7% to 30% in persons aged 75 to 85 years (4–6). The “wet” form of AMD is responsible for the most severe and rapid vision loss. In North America, 200,000 to 400,000 people will develop this form of AMD each year. Wet AMD accounts for 12% of cases overall but 90% of cases of legal blindness (see chap 8 on Wet AMD) (4).

Original languageEnglish (US)
Title of host publicationAge-Related Macular Degeneration, Second Edition
PublisherCRC Press
Number of pages14
ISBN (Electronic)9781420019865
ISBN (Print)9780849372148
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Radiation treatment in age-related macular degeneration'. Together they form a unique fingerprint.

Cite this